Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inbiogen Co. Ltd. (101140:KRX), powered by AI.
Inbiogen Co. Ltd. is currently trading at ₩7,100. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Inbiogen Co. Ltd. on Alpha Lenz.
Inbiogen Co. Ltd.'s P/E ratio is -50.3.
“Inbiogen Co. Ltd. trades at a P/E of -50.3 (undervalued) with modest ROE of -0.9%.”
Ask for details →Inbiogen Co. Ltd. is a biotechnology company engaged in the development and manufacturing of biopharmaceutical products. The primary function of Inbiogen is to innovate and provide therapeutic solutions that address unmet medical needs, with an emphasis on the research and commercialization of novel drugs. Inbiogen plays a significant role in the healthcare sector, contributing to advancements in medical treatments and therapies that cater to a wide range of health conditions. Its focus encompasses areas such as oncology, infectious diseases, and metabolic disorders among others, highlighting its commitment to improving patient outcomes and quality of life. As a participant in the biopharmaceutical industry, Inbiogen's research initiatives and product pipelines are crucial to the sector's growth and competitiveness. With its research and development facilities, the company is at the forefront of pioneering medical breakthroughs and advancing biotechnology innovations on a global scale.
“Inbiogen Co. Ltd. trades at a P/E of -50.3 (undervalued) with modest ROE of -0.9%.”
Ask for details →Inbiogen Co. Ltd. (ticker: 101140) is a company listed on KRX in the Consumer Cyclical sector (Footwear & Accessories). Market cap is $71.3B.
The current price is ₩7,100 with a P/E ratio of -50.27x and P/B of 0.45x.
ROE is -0.89% and operating margin is -68.81%. Annual revenue is $6.3B.